Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800538 | 1.00 | CA2 (0.48) | CA2MAPK1GPR84FFAR1SLC1A2 | |
| SCHEMBL1761848 | 0.86 | — | — | |
| SCHEMBL13294501 | 0.86 | — | — | |
| SCHEMBL29577248 | 0.80 | CA2 (0.50) | CA2MAPK1GPR84FFAR1SLC1A2 | |
| SCHEMBL126679 | 0.80 | CA2 (0.50) | CA2MAPK1GPR84FFAR1SLC1A2 | |
| SCHEMBL14854496 | 0.80 | CA2 (0.50) | CA2MAPK1GPR84FFAR1SLC1A2 | |
| SCHEMBL26542011 | 0.80 | GPR84 (0.34) | CA2MAPK1GPR84FFAR1MAPT | |
| SCHEMBL11315219 | 0.78 | CA2 (0.48) | CA2MAPK1GPR84FFAR1SLC1A2 | |
| SCHEMBL11264534 | 0.78 | CPB2 (0.45) | MAPTSLC6A3HDAC1HDAC2 | |
| SCHEMBL23935444 | 0.77 | GSR (0.52) | MAPTSLC6A3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2023055457-A1 | BACLOFEN-CONTAINING GRANULE FORMULATIONS AND REDUCED PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20120202968-A1 | 2-Amino-3-methyl-hex-5-enoic acid and its use in the prodction of peptides such as bacitracins | XELLIA PHARMACEUTICALS APS (DK) | 2012-08-09 | — | — | US | disclosed |
| WO-2011051071-A1 | 2-AMINO-3-METHYL-HEX-5-ENOIC ACID AND ITS USE IN THE PRODUCTION OF PEPTIDES SUCH AS BACITRACINS | XELLIA PHARMACEUTICALS APS (DK) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051073-A1 | NEW BACITRACIN ANTIBIOTICS | XELLIA PHARMACEUTICALS APS (DK) | 2011-05-05 | — | — | WO | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | CA2 216/4885MAPK1 4736/4885GPR84 2465/4885 |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | CA2 795/4885MAPK1 4132/4885GPR84 634/4885 |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | CA2 795/4885MAPK1 4132/4885GPR84 634/4885 |
| US-20120202968-A1 | 2-Amino-3-methyl-hex-5-enoic acid and its use in the prodction of peptides such as bacitracins | HM13, PEPD, DNPEP | CA2 1859/4885MAPK1 1231/4885GPR84 3128/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | CA2 216/4885MAPK1 4736/4885GPR84 2465/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | CA2 780/4885MAPK1 4086/4885GPR84 618/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | CA2 216/4885MAPK1 4736/4885GPR84 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.